STAT May 22, 2024
Allison DeAngelis

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
Vertex challenger Sionna prices $191M IPO
Insights from JP Morgan 2025: Key trends shaping the pharma industry
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry

Share This Article